Share this Post!

The Food and Drug Administration (FDA) informs all healthcare professionals and the general public that the warning against the purchase and use of FINECARE™ HBA1C TEST as mentioned in FDA Advisory No. 2022-0605 is hereby lifted.

Accordingly, the list released in FDA Advisory No. 2022-0605 is hereby updated to remove the abovementioned medical device.

The issuance of this advisory shall not in any manner preclude this Office from issuing subsequent orders it may deem necessary and appropriate, should there be findings of any violation of the company to existing laws, rules, and regulations.

For more information and inquiries, kindly contact the FDA Center for Device Regulation, Radiation Health, and Research through e-mail at cdrrhr@fda.gov.ph or call (02) 8857-1900 loc. 8301.           

To report any sale or distribution of unnotified medical device, contact the online reporting facility, eReport, through e-mail at ereport@fda.gov.ph.

Dissemination of this advisory to all concerned is hereby requested.

Attachments